Abstract:Carbamazepine (CBZ), a Biopharmaceutics Classification System (BCS) class II drug, is widely-used as a first line antiepileptic drug. Numbers of cocrystals have reported to regulate its poor solubility. However, the solubility behaviors are rarely discussed on theoretical calculations and phase solubility diagrams. In this study, two new drug-drug cocrystals (DDC) of CBZ with emodin (EMO, 1: 1) and paeonol (PAE, 1: 1) as conformers, which offer the advantages of synergetic therapy and patient compliance are reported for the first time. The solubilities in water and in pH = 1.2, 6.8 buffer solutions, demonstrating that the rank order is as follows: CBZ-PAE > CBZ > CBZ-EMO. CBZ-PAE presents the biggest solubility at 0.563 ± 0.003 mmoL/L of in water among all the investigated samples. The solubilities of all the starting materials and cocrystals in six pure organic solvents such as methanol, ethanol, 2-propanol, acetone, acetonitrile, ethyl acetate were investigated to discuss the phase solubility diagrams. The results indicate that experimental solubilities are consistent with the theoretical solubilities on consideration of solubility product (Ksp) and solution binding constant (K11) together. The enthalpy differences between cocrystal and its coformer are calculated through the Perdew-Burke-Ernzerhof (PBE) functional with the projector augmented wave (PAW) pseudopotentials. CBZ-EMO presents the lowest enthalpy (−0.38 kcal/mol) with a highly unfavorable solvation energy (2.42 kcal/mol), resulting in unfavorable in an aqueous environment. Overall, the phase solubility diagrams and theoretical calculations support the solubility regulations on DDCs of CBZ.

Using synchrotron high-resolution powder X-ray diffraction for the structure determination of a new cocrystal formed by two active principle ingredients

Sildenafil–Resorcinol Cocrystal: XRPD Structure and DFT Calculations

Structure Determination and 3D ED/MicroED-Guided Synthesis of a New (S)-Ibuprofen-l-phenylalanine Co-Crystal

Structural Characterization of Pharmaceutical Cocrystals with the Use of Laboratory X-ray Powder Diffraction Patterns

Carbamazepine Cocrystals with Several Aromatic Carboxylic Acids in Different Stoichiometries: Structures and Solid State Characterization

Virtual Screening, Structural Analysis, and Formation Thermodynamics of Carbamazepine Cocrystals

Cocrystals of carbamazepine: Structure, mechanical properties, fluorescence properties, solubility and dissolution rate

Crystal Structure of a New 1:1 Acridine-Diclofenac Salt, Obtained with High Yield by a Mechanochemical Approach

Phase solubility investigation and theoretical calculations on drug-drug cocrystals of carbamazepine with Emodin, Paeonol

Similar but Not the Same: Difference in the Ability to Form Cocrystals Between Nimesulide and the Pyridine Analogues

X-Ray Diffraction and Theoretical Calculation-Supported Formation of Polymorphic Cocrystals Discovered Through Thermal Methods: A Case Study

Relationship between synthesis methodق°±crystal structureق°±melting properties in coآجcrystals: the case of caffeineق°±citric acid

Exploring the formation and diversity of secnidazole cocrystals

Terahertz spectroscopic characterizations and DFT calculations of carbamazepine cocrystals with nicotinamide, saccharin and fumaric acid.

Thermodynamic Investigation of Carbamazepine-Saccharin Co-Crystal Polymorphs

Two Novel Cocrystals of Lamotrigine with Isomeric Bipyridines and in Situ Monitoring of the Cocrystallization.

Low-Frequency Vibrational Spectroscopy Characteristic of Pharmaceutical Carbamazepine Co-Crystals with Nicotinamide and Saccharin

Microelectron Diffraction Reveals Contamination of Polymorphs by Structure Analysis of Microscale Crystals in a Novel Pharmaceutical Cocrystal

Powder X-ray Diffraction of 1-(4-aminophenyl)-5,6-dihydro-3-(4-morpholinyl)-2(1h)-pyridinone, C15H19N3O2

Formation Thermodynamics of Carbamazepine with Benzamide, Para-Hydroxybenzamide and Isonicotinamide Cocrystals: Experimental and Theoretical Study

Synthesis, Powder Diffraction Pattern, Crystal Structure Determination of the Pharmaceutical Co-Crystal of Levetiracetam and 3,5-Dinitrosalicylic Acid